doravirine/lamivudine/tenofovir

Official Site for DELSTRIGO (doravirine/lamivudine/tenofovir disoproxil fumarate).

Doravirine, also known by its brand name Pifeltro, is a medication that has been approved by the FDA for the treatment of HIV infection in both adults and children who weigh at least 77 lb (35 kg) and meet specific criteria set by a healthcare professional.

It’s important to note that lamivudine and tenofovir are also sold separately under the brand names Epivir, Epivir-HBV (for hepatitis B treatment), Vemlidy (for hepatitis B treatment), and Viread. They are also available in combination with other medications under the brand names Atripla, Biktarvy, Combivir, Complera, Descovy, and others.

Tenofovir disoproxil fumarate, also known as Tenofovir, is a medication available in both generic and brand-name forms. The brand names for Tenofovir are Viread and Vemlidy. It can be taken as an oral tablet or as an oral powder. Tenofovir oral tablet is approved for the treatment of HIV infection and chronic hepatitis B virus infection.

On August 30, 2018, PIFELTRO and DELSTRIGO received approval in the United States for treating HIV-1 infection in adults who have not previously undergone antiretroviral treatment.

The medication you are taking is called Truvada, which contains the active drugs tenofovir disoproxil fumarate (equivalent to 245mg of tenofovir) and emtricitabine.

Pifeltro, a medication developed by Merck & Co., is a non-nucleoside reverse transcriptase inhibitor known by its generic name, Doravirine.

INTELENCE (etravirine) is a medication that belongs to the class of non-nucleoside reverse transcriptase inhibitors (NNRTIs). It is used to treat human immunodeficiency virus type 1 (HIV-1) infections.

The bioavailability of doravirine is 64%, meaning that 64% of the administered dose is absorbed into the bloodstream. The maximum concentration of doravirine in the blood (Tmax) occurs 2 hours after oral administration. When [14C]doravirine was given orally, the entire dose was recovered, indicating that the drug is well absorbed.

TRIUMEQ is a medication that comes in pill form and is composed of abacavir, dolutegravir, and lamivudine. Additionally, TRIUMEQ is offered in the form of tablets that can be taken orally, known as TRIUMEQ PD.

The combination of lamivudine and tenofovir is administered alongside other antiviral medications to treat HIV infection, which is caused by the human immunodeficiency virus (HIV) and leads to acquired immune deficiency syndrome (AIDS).

Tenofovir alafenamide (AF), also known as Vemlidy, is prescribed to adults and children aged 12 and above with stable liver disease to treat chronic HBV. It belongs to a group of drugs called nucleoside reverse transcriptase inhibitors (NRTIs) and functions by reducing the levels of HIV and HBV in the bloodstream.

Tenofovir is administered in combination with other HIV medications to effectively manage HIV infection. By reducing the level of HIV in the body, it enhances the functioning of the immune system. Consequently, the risk of experiencing HIV-related complications, such as new infections and cancer, is reduced, leading to an improved quality of life.

Wait for your doctor’s instructions before beginning to use tenofovir. It is important to note that there are two uncommon yet severe reactions associated with this medication, namely lactic acidosis (accumulation of acid in the blood) and liver toxicity. These reactions are more prevalent in females, individuals who are significantly overweight (obese), or those who have been on antiviral medications for an extended period.

According to a study by Marcellin et al, patients who were given tenofovir consistently for 240 weeks experienced long-term suppression of HBV DNA levels, with 83% of HBeAg-negative patients and 65% of HBeAg-positive patients maintaining levels below 400 copies/mL.

Symptoms include headache, diarrhea, heartburn, difficulty sleeping, depression, stuffy nose, cough, and joint pain.

If you experience any of the following symptoms while taking Tenofovir, it is important to seek immediate medical attention as they may indicate a potentially life-threatening condition called lactic acidosis: unusual muscle pain, difficulty breathing, stomach pain, vomiting, fast or slow heartbeats, irregular heartbeats, dizziness, feeling cold, extreme weakness, or excessive fatigue.

Clinical trials have shown that tenofovir is a safe and effective treatment for patients with chronic hepatitis B, resulting in high rates of sustained virological suppression.

Tenofovir disoproxil fumarate (TDF) exhibits enhanced antiviral activity and a greater resistance to genetic mutations compared to LAM, making it a more potent oral nucleotide analog.

The combination of lamivudine and tenofovir is prescribed alongside other drugs to treat HIV in both adults and children. These medications, classified as nucleoside and nucleotide reverse transcriptase inhibitors (NRTIs), function by inhibiting the replication of HIV in the body, thereby reducing its progression.

Both the World Health Organization (WHO) and the US President’s Emergency Plan for AIDS Relief recommend the use of oral pre-exposure prophylaxis (PrEP) for individuals at high risk of HIV infection. This PrEP contains a combination of tenofovir disoproxil fumarate (TDF) with either emtricitabine (FTC) or lamivudine (3TC).

In general, cisgender men who are taking on-demand PrEP should continue taking the medication for a minimum of 2 days after a potential exposure. However, individuals who are taking daily PrEP should continue taking the medication for a duration of 28 days after the last possible exposure.

Doravirine is prescribed in combination with other drugs to treat HIV infection in adults who have not previously received HIV medication. It can also be used as a replacement therapy for individuals already on HIV medication.

Doravirine has been approved for the treatment of HIV-1 infection in adult patients who have not previously received antiretroviral treatment. This provides additional options for managing HIV-1 infection.

BIKTARVY is a once-daily prescription medication that is taken as a single pill. It is used to treat HIV-1 in both adults and children who weigh at least 55 pounds.

Biktarvy is generally not recommended, but it may be considered for use in adults with end stage renal disease (estimated CrCl < 15 mL/min) who are on chronic hemodialysis if the potential benefits are deemed to outweigh the potential risks (see section 4.2).

Drotaverine acts as a smooth muscle relaxant by inhibiting phosphodiesterase, which leads to an increase in cAMP concentration. This, in turn, decreases the uptake of calcium by the cells and alters the distribution of calcium within the cells. Additionally, Drotaverine may have some minor allosteric calcium channel blocking effects.

BIKTARVY is a comprehensive treatment for HIV-1 that consists of three potent medications in a single daily pill, which can be taken with or without food. It is important not to take BIKTARVY alongside other HIV-1 medications. However, it is crucial to note that BIKTARVY does not provide a cure for HIV-1 or AIDS. HIV-1 is the virus responsible for causing AIDS.

Some common side effects of doravirine may include abnormal dreams, difficulty sleeping, nightmares, depression, headaches, dizziness, drowsiness, nausea, diarrhea, abdominal pain, vomiting, rash, and tiredness.

At week 48, 8-10% of participants experienced a weight gain of 10% or more. This percentage increased to 14-16% at week 96 (Fig. X).

Hepatotoxicity was observed in 13% of patients receiving doravirine therapy, with only a small percentage (1% or less) experiencing elevations in serum aminotransferase levels exceeding 5 times the upper limit of normal.

PIFELTRO is a prescription medication for treating HIV-1 infection in adults who have not previously taken HIV-1 medicines or for those who need to switch their current HIV-1 medicines based on their healthcare provider’s assessment.

Information on Pifeltro pricing, discounts, and patient assistance programs. Pifeltro, a medication in the NNRTIs drug class used for HIV Infection, typically costs around $1,775 for a 30-tablet supply of the 100 mg oral tablet, but prices may vary by pharmacy.

Biktarvy has the potential to result in severe and life-threatening adverse effects. These may encompass the accumulation of lactic acid in the bloodstream (known as lactic acidosis), complications with liver function, the development or exacerbation of kidney problems, including the possibility of kidney failure, as well as potential interactions with other medications.

Some of the common side effects of Delstrigo are abnormal dreams, difficulty sleeping, nightmares, depression, headaches, dizziness, drowsiness, coughing, an irritated or runny nose, nausea, diarrhea, abdominal pain, vomiting, hair loss, rashes, muscle disorders, fatigue, and fever.

While doravirine may possess a greater genetic barrier to resistance when compared to first-generation NNRTIs, second-generation INSTIs (such as dolutegravir and bictegravir) and PIs are more lenient in cases of medication non-adherence and have stronger genetic barriers to resistance.

You should take one DELSTRIGO pill once a day, at approximately the same time each day, with or without food.

Doravirine, also known by its brand name Pifeltro, is a medication that has been approved by the FDA for the treatment of HIV infection in both adults and children who weigh at least 77 lb (35 kg) and meet specific criteria set by a healthcare professional.

Lamivudine is classified as a nucleoside reverse transcriptase inhibitor (NRTI) and is commonly prescribed for the management and treatment of HIV-1 and hepatitis B.

Biktarvy has the potential to induce depression, with some studies showing that individuals taking Biktarvy experienced suicidal thoughts or attempted suicide. Clinical studies have found that depression occurred in less than 2% of Biktarvy users.